Does the media favor ENTA or INVA?

In the previous week, Innoviva had 1 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 6 mentions for Innoviva and 5 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 1.74 beat Innoviva's score of 1.29 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enanta Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Innoviva 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer HROW or ENTA?

In the previous week, Harrow and Harrow both had 5 articles in the media. Harrow's average media sentiment score of 1.76 beat Enanta Pharmaceuticals' score of 1.74 indicating that Harrow is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Enanta Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer PAHC or ENTA?

In the previous week, Phibro Animal Health had 14 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 19 mentions for Phibro Animal Health and 5 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 1.74 beat Phibro Animal Health's score of 0.77 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 7 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enanta Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer ENTA or SPTX?

In the previous week, Seaport Therapeutics had 2 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 7 mentions for Seaport Therapeutics and 5 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 1.74 beat Seaport Therapeutics' score of 0.43 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enanta Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Seaport Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ENTA or EYPT?

In the previous week, Eyepoint Pharmaceuticals had 5 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 10 mentions for Eyepoint Pharmaceuticals and 5 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 1.74 beat Eyepoint Pharmaceuticals' score of 0.21 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enanta Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Eyepoint Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Enanta Pharmaceuticals (ENTA) Competitors

$13.60 -0.20 (-1.45%)

As of 08/28/2026 04:00 PM Eastern

Compare

ENTA vs. INVA, HROW, PAHC, SPTX, and EYPT

Should you buy Enanta Pharmaceuticals stock or one of its competitors? Enanta Pharmaceuticals's main competitors and comparable companies include Innoviva (INVA), Harrow (HROW), Phibro Animal Health (PAHC), Seaport Therapeutics (SPTX), and Eyepoint Pharmaceuticals (EYPT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Enanta Pharmaceuticals compare to Innoviva?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Innoviva (NASDAQ:INVA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Innoviva has higher revenue and earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	6.06	-$81.89M	-$2.41	N/A
Innoviva	$440.00M	3.44	$271.17M	$4.10	5.11

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 11.5% of Enanta Pharmaceuticals shares are held by company insiders. Comparatively, 2.0% of Innoviva shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Enanta Pharmaceuticals currently has a consensus price target of $19.50, indicating a potential upside of 43.38%. Innoviva has a consensus price target of $34.75, indicating a potential upside of 65.71%. Given Innoviva's higher probable upside, analysts clearly believe Innoviva is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Innoviva	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17

In the previous week, Innoviva had 1 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 6 mentions for Innoviva and 5 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 1.74 beat Innoviva's score of 1.29 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enanta Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Innoviva	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Innoviva has a net margin of 81.19% compared to Enanta Pharmaceuticals' net margin of -96.89%. Innoviva's return on equity of 28.03% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%
Innoviva	81.19%	28.03%	20.19%

Enanta Pharmaceuticals has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, Innoviva has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Summary

Innoviva beats Enanta Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Harrow?

Harrow (NASDAQ:HROW) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Harrow currently has a consensus target price of $69.43, indicating a potential upside of 86.29%. Enanta Pharmaceuticals has a consensus target price of $19.50, indicating a potential upside of 43.38%. Given Harrow's higher probable upside, equities analysts plainly believe Harrow is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Harrow has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market.

In the previous week, Harrow and Harrow both had 5 articles in the media. Harrow's average media sentiment score of 1.76 beat Enanta Pharmaceuticals' score of 1.74 indicating that Harrow is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harrow	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Enanta Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

72.8% of Harrow shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 12.8% of Harrow shares are owned by company insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Harrow has a net margin of -13.51% compared to Enanta Pharmaceuticals' net margin of -96.89%. Harrow's return on equity of -38.00% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-13.51%	-38.00%	-3.37%
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%

Harrow has higher revenue and earnings than Enanta Pharmaceuticals. Harrow is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$275.59M	5.07	-$5.14M	-$1.00	N/A
Enanta Pharmaceuticals	$65.32M	6.06	-$81.89M	-$2.41	N/A

Summary

Harrow beats Enanta Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Phibro Animal Health?

Phibro Animal Health (NASDAQ:PAHC) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

In the previous week, Phibro Animal Health had 14 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 19 mentions for Phibro Animal Health and 5 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 1.74 beat Phibro Animal Health's score of 0.77 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	7 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enanta Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Phibro Animal Health currently has a consensus target price of $47.67, indicating a potential upside of 26.54%. Enanta Pharmaceuticals has a consensus target price of $19.50, indicating a potential upside of 43.38%. Given Enanta Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Phibro Animal Health has a net margin of 6.57% compared to Enanta Pharmaceuticals' net margin of -96.89%. Phibro Animal Health's return on equity of 37.86% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.57%	37.86%	9.18%
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%

99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by company insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Phibro Animal Health has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

Phibro Animal Health has higher revenue and earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.52B	1.01	$48.26M	$2.44	15.44
Enanta Pharmaceuticals	$65.32M	6.06	-$81.89M	-$2.41	N/A

Summary

Phibro Animal Health beats Enanta Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Seaport Therapeutics?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Seaport Therapeutics (NASDAQ:SPTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

In the previous week, Seaport Therapeutics had 2 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 7 mentions for Seaport Therapeutics and 5 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 1.74 beat Seaport Therapeutics' score of 0.43 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enanta Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Seaport Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Seaport Therapeutics has lower revenue, but higher earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Seaport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	6.06	-$81.89M	-$2.41	N/A
Seaport Therapeutics	N/A	N/A	-$74.88M	-$12.12	N/A

Seaport Therapeutics has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -96.89%. Seaport Therapeutics' return on equity of 0.00% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%
Seaport Therapeutics	N/A	N/A	N/A

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Enanta Pharmaceuticals presently has a consensus target price of $19.50, suggesting a potential upside of 43.38%. Seaport Therapeutics has a consensus target price of $37.33, suggesting a potential upside of 55.30%. Given Seaport Therapeutics' higher probable upside, analysts plainly believe Seaport Therapeutics is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Seaport Therapeutics	2 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.36

Summary

Seaport Therapeutics beats Enanta Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Eyepoint Pharmaceuticals?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

In the previous week, Eyepoint Pharmaceuticals had 5 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 10 mentions for Eyepoint Pharmaceuticals and 5 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 1.74 beat Eyepoint Pharmaceuticals' score of 0.21 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enanta Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enanta Pharmaceuticals has higher revenue and earnings than Eyepoint Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	6.06	-$81.89M	-$2.41	N/A
Eyepoint Pharmaceuticals	$31.37M	12.31	-$231.96M	-$3.74	N/A

Enanta Pharmaceuticals has a net margin of -96.89% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Enanta Pharmaceuticals' return on equity of -61.84% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%

Enanta Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market.

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. 11.5% of Enanta Pharmaceuticals shares are held by company insiders. Comparatively, 5.1% of Eyepoint Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Enanta Pharmaceuticals presently has a consensus price target of $19.50, indicating a potential upside of 43.38%. Eyepoint Pharmaceuticals has a consensus price target of $28.11, indicating a potential upside of 527.48%. Given Eyepoint Pharmaceuticals' higher possible upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Eyepoint Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.45

Summary

Enanta Pharmaceuticals beats Eyepoint Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

Get Enanta Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENTA vs. The Competition

Export

Metric	Enanta Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$396.10M	$12.15B	$7.20B	$12.90B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	-5.64	787.65	273.16	25.45
Price / Sales	6.06	793.10	605.06	76.64
Price / Cash	N/A	91.95	76.74	53.00
Price / Book	3.92	11.97	12.98	6.14
Net Income	-$81.89M	$2.83B	$3.48B	$348.86M
7 Day Performance	0.97%	0.39%	0.13%	-0.80%
1 Month Performance	4.62%	5.34%	7.08%	4.13%
1 Year Performance	61.90%	6.05%	24.67%	15.17%

Enanta Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENTA Enanta Pharmaceuticals	1.9643 of 5 stars	$13.60 -1.4%	$19.50 +43.4%	+61.9%	$396.10M	$65.32M	N/A	160	News Coverage
INVA Innoviva	3.3405 of 5 stars	$21.25 +1.4%	$34.75 +63.5%	+2.6%	$1.53B	$411.33M	5.18	100	Positive News
HROW Harrow	3.0021 of 5 stars	$39.52 +0.1%	$69.43 +75.7%	-4.4%	$1.50B	$272.30M	N/A	180
PAHC Phibro Animal Health	4.1696 of 5 stars	$34.65 +0.1%	$42.50 +22.7%	+1.6%	$1.39B	$1.30B	14.87	2,475	News Coverage Earnings Report
SPTX Seaport Therapeutics	2.9104 of 5 stars	$23.97 -1.8%	$38.40 +60.2%	N/A	$1.30B	N/A	N/A	N/A	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENTA) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enanta Pharmaceuticals (ENTA) Competitors

ENTA vs. INVA, HROW, PAHC, SPTX, and EYPT

How does Enanta Pharmaceuticals compare to Innoviva?

Summary

How does Enanta Pharmaceuticals compare to Harrow?

Summary

How does Enanta Pharmaceuticals compare to Phibro Animal Health?

Summary

How does Enanta Pharmaceuticals compare to Seaport Therapeutics?

Summary

How does Enanta Pharmaceuticals compare to Eyepoint Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTA vs. The Competition

Enanta Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enanta Pharmaceuticals (ENTA) Competitors

ENTA vs. INVA, HROW, PAHC, SPTX, and EYPT

How does Enanta Pharmaceuticals compare to Innoviva?

Which has preferable earnings & valuation, ENTA or INVA?

Do insiders & institutionals have more ownership in ENTA or INVA?

Do analysts rate ENTA or INVA?

Does the media favor ENTA or INVA?

Is ENTA or INVA more profitable?

Which has more risk & volatility, ENTA or INVA?

Summary

How does Enanta Pharmaceuticals compare to Harrow?

Do analysts rate HROW or ENTA?

Which has more risk and volatility, HROW or ENTA?

Does the media prefer HROW or ENTA?

Do insiders and institutionals believe in HROW or ENTA?

Is HROW or ENTA more profitable?

Which has higher earnings & valuation, HROW or ENTA?

Summary

How does Enanta Pharmaceuticals compare to Phibro Animal Health?

Does the media prefer PAHC or ENTA?

Do analysts prefer PAHC or ENTA?

Is PAHC or ENTA more profitable?

Do institutionals and insiders have more ownership in PAHC or ENTA?

Which has more risk and volatility, PAHC or ENTA?

Which has preferable earnings and valuation, PAHC or ENTA?

Summary

How does Enanta Pharmaceuticals compare to Seaport Therapeutics?

Does the media prefer ENTA or SPTX?

Which has preferable valuation & earnings, ENTA or SPTX?

Is ENTA or SPTX more profitable?

Do institutionals & insiders hold more shares of ENTA or SPTX?

Do analysts prefer ENTA or SPTX?

Summary

How does Enanta Pharmaceuticals compare to Eyepoint Pharmaceuticals?

Does the media refer more to ENTA or EYPT?

Which has preferable valuation and earnings, ENTA or EYPT?

Is ENTA or EYPT more profitable?

Which has more volatility & risk, ENTA or EYPT?

Do insiders & institutionals believe in ENTA or EYPT?

Do analysts prefer ENTA or EYPT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTA vs. The Competition

Enanta Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools